Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Biomol Screen ; 16(9): 1098-105, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21821827

RESUMEN

P2Y14 is a member of the pyrimidinergic GPCR family. UDP-Glc has been previously shown to activate human P2Y14, whereas UDP was unable to activate the receptor. In this study, the authors used conventional and nonconventional methods to further characterize P2Y14 and its ligands. Conventional calcium mobilization and nonconventional cellular impedance functional assays revealed that UMP and UDP selectively activated HEK cells coexpressing P2Y14 and Gα(qi5). In the impedance assays, the presence of exogenous Gα(qi5) resulted in agonist-induced Gq signaling, whereas in the absence of exogenous Gα(qi5), the signal was indicative of Gi. The authors established the first P2Y14 membrane filtration binding assay using a novel optimized expression vector and [(3)H]UDP as radioligand. UDP-Glc, UMP, and UDP dose dependently inhibited [(3)H]UDP binding in the binding assay, and saturation analysis revealed that UDP bound P2Y14 with a K(D) = 10 nM and a B(max) = 110 pmol/mg. The authors screened a phosphonate library and identified compound A, which inhibited UDP-Glc-mediated calcium signaling in the fluorometric imaging plate reader assay (IC(50) = 2.3 µM) and competed for [(3)H]UDP binding in the novel binding assay with a K(i) = 1280 nM.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Agonistas del Receptor Purinérgico P2/farmacología , Antagonistas del Receptor Purinérgico P2/farmacología , Receptores Purinérgicos P2/metabolismo , Animales , Línea Celular Transformada , Relación Dosis-Respuesta a Droga , Regulación de la Expresión Génica/efectos de los fármacos , Células HEK293 , Humanos , Ligandos , Ratones , Pan troglodytes , Unión Proteica , Receptores Purinérgicos P2/genética , Transducción de Señal/efectos de los fármacos
2.
J Chem Inf Model ; 47(2): 488-508, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17288412

RESUMEN

Many metrics are currently used to evaluate the performance of ranking methods in virtual screening (VS), for instance, the area under the receiver operating characteristic curve (ROC), the area under the accumulation curve (AUAC), the average rank of actives, the enrichment factor (EF), and the robust initial enhancement (RIE) proposed by Sheridan et al. In this work, we show that the ROC, the AUAC, and the average rank metrics have the same inappropriate behaviors that make them poor metrics for comparing VS methods whose purpose is to rank actives early in an ordered list (the "early recognition problem"). In doing so, we derive mathematical formulas that relate those metrics together. Moreover, we show that the EF metric is not sensitive to ranking performance before and after the cutoff. Instead, we formally generalize the ROC metric to the early recognition problem which leads us to propose a novel metric called the Boltzmann-enhanced discrimination of receiver operating characteristic that turns out to contain the discrimination power of the RIE metric but incorporates the statistical significance from ROC and its well-behaved boundaries. Finally, two major sources of errors, namely, the statistical error and the "saturation effects", are examined. This leads to practical recommendations for the number of actives, the number of inactives, and the "early recognition" importance parameter that one should use when comparing ranking methods. Although this work is applied specifically to VS, it is general and can be used to analyze any method that needs to segregate actives toward the front of a rank-ordered list.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Biología Computacional , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA